Dexmedetomidine is a well-known alpha 2 adrenergic agonist and widely used drug. First approved by Food and Drug Administration (FDA) in 1999 as a sedative, now dexmedetomidine has been a focus of extensive research because of its anti-inflammatory, sympatholytic actions. In a recent study Brandao et al. has described significantly lower reoperation rate, neurological injury, decrease hospital stay and improved thirty day mortality in their retrospective analysis of cardiac surgical patients who received dexmedetomidine during procedure [1].
http://ift.tt/2sIATIz
Παρασκευή 16 Ιουνίου 2017
Dexmedetomidine and Renal Protection after Cardiac Surgery
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου